Quick Facts

• May be utilized to address acute bacterial exacerbations of chronic bronchitis.
• May be used in the treatment of complicated and uncomplicated urinary tract infections (UTIs).
• May be administered pre-operatively to help reduce the incidence of UTIs following transurethral surgical procedures.

---

Maxaquin (lomefloxacin hydrochloride) is a medication that may be considered for the management of specific bacterial infections in adults. The primary therapeutic domains for this option involve infections of the respiratory and urinary systems.

This agent is indicated for the treatment of mild to moderate bacterial infections when caused by susceptible microorganisms. Its approved uses include the treatment of both complicated and uncomplicated urinary tract infections.

Furthermore, the medication may be utilized to address acute bacterial exacerbations of chronic bronchitis. This therapy may provide a beneficial effect for individuals seeking to manage these conditions. The drug is also used as a preventative measure to reduce the incidence of urinary tract infections in the early postoperative period for patients undergoing transurethral surgical procedures.

Maxaquin (lomefloxacin) is approved strictly for use in adult patients (18 years and older) for specific bacterial infections. The official regulatory profile prohibits or restricts its use in several populations.

Eligibility Scope

Classification	Population/Condition
Contraindicated	Patients with known hypersensitivity to lomefloxacin or any other quinolone antibiotic.
Contraindicated	Pediatric and Adolescent Patients (under 18 years) due to safety concerns regarding developing joints.
Not Recommended	Pregnant or Breastfeeding Women; use is not recommended due to potential risk to the fetus or infant.
Conditional Use	Geriatric Patients and patients with renal impairment require special caution due to an increased risk of tendon damage or altered drug clearance.
Restricted Use	Patients with a history of tendon disorders, CNS disorders that predispose to seizures, or Myasthenia Gravis (risk of exacerbation).

Resulting Eligibility Structure

Official regulatory documents define Maxaquin as an antimicrobial reserved strictly for adult patients whose clinical status does not include a history of quinolone allergy or other specific high-risk vulnerabilities. The eligibility profile is structured by absolute contraindications based on hypersensitivity and age, coupled with conditional restrictions mandated for patients with pre-existing risk factors, reflecting the regulatory need to mitigate serious, class-specific risks.

Interactions with Other Medicines and Products

This information describes the officially documented interaction patterns for Maxaquin (lomefloxacin) as specified in government regulatory documents.

---

Documented Pharmacokinetic Interactions

Co-administration with certain products can significantly alter the systemic exposure to Maxaquin. This effect is primarily a pharmacokinetic interaction rooted in chelation.

Interacting Substance/Product	Official Interaction Outcome
Multivalent Cations (e.g., Aluminum- or Magnesium-containing antacids, Iron, Zinc, Sucralfate)	Result in decreased systemic exposure to lomefloxacin (reduced AUC and Cmax) due to complex formation in the gastrointestinal tract.
Food (Concomitant Administration)	Delays the rate of absorption (Tmax increased by 41%) and reduces the extent of absorption (AUC decreased by 12%).

---

Administration Restrictions and Drug-Drug Interactions

Regulatory labeling establishes mandatory timing rules and specifies an interaction with a co-administered medicine.

• Mandatory Timing Rule: Products containing multivalent cations must be administered at least 4 hours after the dose of Maxaquin to mitigate the reduction in absorption.
• Theophylline: Concurrent administration may lead to elevated Theophylline plasma concentrations and has been associated with an increased risk of serious adverse reactions, establishing a major restriction for combined use.
• CYP Enzymes: Maxaquin is documented to be less prone to inhibit Cytochrome P450 1A2 (CYP1A2) compared to ciprofloxacin, defining its specific metabolic interaction profile.

Maxaquin's action begins by selectively targeting two essential bacterial enzymes, DNA Gyrase and Topoisomerase IV, which are vital for managing the pathogen's genetic material. The drug molecules act as selective inhibitors, binding to and stabilizing the intermediate complex where the bacterial DNA has been cleaved. This binding immediately halts the ability of the bacteria to replicate or repair its genetic code.

The stabilization of the cleaved DNA-enzyme complex results in extensive, irreparable damage to the bacterial genome via double-strand DNA breaks. This damage triggers the bacterial SOS response and subsequent activation of autolytic enzymes, forcing the cell into a process of self-destruction. This mechanism produces a rapid bactericidal consequence, leading to the physical destruction of susceptible pathogens, which defines the molecule's core biological function.

Note that the functional potential of this mechanism can be constrained by biological limitations, including bacterial efflux pump systems that transport the drug out of the cell, and structural mutations in the target enzymes (DNA gyrase/Topoisomerase IV). These factors reduce the drug's affinity or concentration at the target, thereby reducing the resulting bactericidal consequence.

How to Use Maxaquin

Maxaquin is taken by mouth. Following the administration instructions is important for the absorption and effectiveness of the medication and for the completion of the prescribed course of therapy.

General Administration Guidelines

Administration Scope	Instruction
Route of Administration	Oral (by mouth)
Dosing Frequency	Twice-daily (e.g., 200 mg or 400 mg every 12 hours) or as a single dose, depending on the prescribed course.
Timing Relative to Meals	Take the medication at least one hour before or at least two hours after a meal.
Concomitant Product Separation	Administration must be separated from products containing multivalent cations (e.g., antacids with magnesium or aluminum, sucralfate, or supplements with iron or zinc) by a minimum of two hours before or six hours after the dose of Maxaquin.

Procedural and Dose Adjustment Rules

It is essential to complete the full prescribed course of Maxaquin, even if symptoms begin to improve sooner, unless a healthcare provider directs otherwise. Patients with reduced renal function (creatinine clearance < 30 mL/min/1.73 m^2) receive a reduced dose—specifically one-half the recommended dose every 12 hours, following a normal initial dose. Maintaining adequate hydration by drinking plenty of extra fluids is advised during treatment.

Research Evidence / Overview of Studies for Maxaquin

Research Evidence for Urinary Tract Infections (UTIs)

Studies were conducted to evaluate Maxaquin in adults experiencing acute symptoms related to urinary tract infections. Specifically, researchers measured clinical resolution (how symptoms evolved in the observed populations) and bacteriological response (patterns in the presence of the causative organism).

The evidence is derived from multi-center trials, including randomized studies that involved comparisons against other antibacterial agents. These trials reported patterns related to the evolution of symptoms and the presence of bacteria. For example, some studies reported that measured changes in outcomes for Maxaquin were observed to be similar to those seen with the comparator agents over the study period.

Uncertainty in the evidence context stems partly from the broader drug class. Regulatory bodies have issued advice suggesting restrictions on the use of fluoroquinolones for some uncomplicated infections, which influences the interpretation of the existing evidence, even if initial findings were comparable to other treatments.

Research Evidence for Acute Exacerbations of Chronic Bronchitis

Studies examining Maxaquin for conditions characterized by acute or disruptive episodes, such as acute bacterial exacerbations of chronic bronchitis, used controlled research scenarios. Research explored short-term symptom changes, monitoring outcomes reflecting daily functioning and patient-reported outcomes describing perceived discomfort.

Findings reported patterns related to clinical response (assessing the evolution of symptoms) and microbiological response (evaluating patterns in the targeted bacteria). These outcomes were typically measured within a short, defined time interval after starting the antibacterial treatment.

What is still uncertain is that regulatory assessments of the drug class have noted challenges in reliably quantifying the magnitude of effect when comparing antibacterial therapy to non-treatment in certain patient groups. Long-term effects on subsequent exacerbation frequency are not fully established.

Research Evidence for Surgical Prophylaxis

This section will detail the controlled clinical trials and comparative studies that investigated the use of Maxaquin in research settings where the incidence of UTIs was monitored following transurethral surgical procedures.

The primary outcomes studied were the measured patterns in the incidence of postoperative UTIs and bacteriuria rates (the presence of bacteria in urine). Research highlights measured changes in infection rates that were observed to be similar to those seen with the comparator agents.

What remains uncertain is that the evidence is mainly derived from trials comparing the drug to an active antibiotic, meaning comparative evidence against no treatment is often lacking. Additionally, the follow-up durations were typically limited to the immediate short-term period after surgery, and there is limited information for long-term outcomes following the prophylactic administration.

Common questions about Maxaquin (FAQ)

Q: How quickly does Maxaquin usually start working for an infection?

A: Official information regarding Maxaquin's function explains that its mechanism is designed to cause a rapid bactericidal effect on susceptible bacteria. However, the exact time it takes for a patient to notice clinical improvement, such as symptom relief, is not typically quantified in regulatory documents.

---

Q: Is it common to feel dizzy or lightheaded after starting Maxaquin?

A: Regulatory documents list dizziness as a documented adverse reaction that may occur when taking Maxaquin. The full official prescribing information contains details on the frequency of this and other side effects as observed in clinical studies.

---

Q: Can Maxaquin affect sleep patterns?

A: Yes, official safety information indicates that Maxaquin, like other drugs in its class, can sometimes cause central nervous system (CNS) side effects. Insomnia (difficulty sleeping) is specifically listed as a documented reaction.

---

Q: How long does Maxaquin stay in your system after the last dose?

A: According to the official pharmacokinetics data, Maxaquin (lomefloxacin) has an elimination half-life of approximately 7 to 8 hours in adults with normal renal function. Based on pharmacokinetics, the drug is substantially eliminated from the body within about 72 hours, though individual variation exists.

---

Q: Is it possible to become resistant to Maxaquin over time?

A: Yes, regulatory documents describe the potential for bacteria to develop resistance to this class of antibiotics. Resistance can occur through biological limitations like mutations in the bacterial DNA enzymes, which reduces the drug's ability to be effective.

---

Q: Why do some people experience ringing in the ears (tinnitus) while taking Maxaquin?

A: Official safety documents list tinnitus (ringing in the ears) as a documented adverse event. This reaction is generally grouped with other potential effects on the nervous system that are associated with Maxaquin.

---

Q: Does Maxaquin interact with oral contraceptives (birth control pills)?

A: Specific drug interaction studies between Maxaquin and common oral contraceptives are typically not documented in the regulatory label. This indicates that a clinically significant interaction is not formally established by the manufacturer.

---

Q: How does Maxaquin's half-life affect how often it is dosed?

A: The drug’s half-life of approximately 8 hours influences the prescribed dosing schedule. This half-life is intended to help maintain consistent levels of the antibiotic in the body when taken as prescribed.

---

Q: What happens if a dose of Maxaquin is missed?

A: Official regulatory guidance generally states that if a dose is missed, it can be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. It is explicitly advised not to double the dose to make up for a missed one.

---

Q: Does Maxaquin require a special diet during the treatment period?

A: Maxaquin does not require a special diet, but the medication should be separated by several hours from antacids or supplements that contain multivalent cations (like aluminum, magnesium, iron, or zinc). This separation is necessary because these substances can significantly reduce the drug’s absorption.

---

Q: Can Maxaquin change the results of certain lab tests?

A: Yes, official warnings indicate that Maxaquin can interfere with specific laboratory screening tests. This interference may lead to false-positive results for certain substances, such as opiates or benzodiazepines, in urine tests.

---

Q: Are there any long-term side effects associated with Maxaquin use?

A: Official warnings note that serious adverse reactions, particularly peripheral neuropathy (nerve damage), can be disabling and potentially irreversible. These effects may be delayed, occurring up to several months after discontinuing the drug.

---

Q: Do people often experience heartburn or stomach upset with Maxaquin?

A: Official safety data confirms that gastrointestinal issues are documented side effects of Maxaquin, including nausea and diarrhea. Other related issues like stomach upset or heartburn may also be listed in the full adverse event data tables.

---

Q: Is there a risk of mental or mood changes while on Maxaquin?

A: Yes, regulatory warnings state that Maxaquin carries a risk of mental and mood disturbances. Documented reactions include, but are not limited to, anxiety, depression, hallucinations, and suicidal ideation/behavior.

---

Q: Is Maxaquin ever used to treat sexually transmitted infections (STIs)?

A: The approved uses (indications) for Maxaquin are established by regulatory bodies for specific bacterial infections. These typically include Urinary Tract Infections (UTIs), exacerbations of Chronic Bronchitis, and Surgical Prophylaxis for certain procedures. STIs are generally not listed as approved indications.

---

Q: What are the ingredients in Maxaquin besides the active drug?

A: Maxaquin tablets contain the active drug substance, Lomefloxacin hydrochloride, along with several inactive ingredients (excipients). These excipients are standard pharmaceutical materials, such as fillers, coloring agents, and binders, which are necessary to form the tablet. The full list is detailed in the official product information.

---

Q: Do people with kidney problems need a different Maxaquin dosage?

A: Yes, official administration guidelines require a dosage adjustment for individuals with reduced renal function (kidney impairment). To prevent the drug from building up in the body, these patients typically require a reduced dose compared to those with normal kidney function.

---

Q: Can Maxaquin cause changes in blood sugar levels?

A: Official warnings associated with the drug class note that Maxaquin can cause disturbances in blood glucose levels. These disturbances can manifest as both excessively low blood sugar (hypoglycemia) or excessively high blood sugar (hyperglycemia).

---

Q: What kind of monitoring is needed while taking Maxaquin?

A: Regulatory documents advise that monitoring may be necessary during treatment for certain high-risk situations. This includes monitoring of renal function for dose adjustments, and monitoring of the QT interval (a measure of heart rhythm) in patients at risk for heart-related issues.

---

Q: Is there a maximum time a person can safely be on Maxaquin?

A: Official regulatory guidance defines a specific maximum duration of treatment for each of Maxaquin’s approved uses (e.g., a maximum of 10 days for certain infections). Regulatory guidance states that treatment duration should align with the established timeframes for the specific approved indication.

Storage and Disposal Requirements for Maxaquin (Lomefloxacin Hydrochloride) Tablets

The storage of Maxaquin tablets must adhere to official regulatory conditions to ensure product integrity.

Requirement Domain	Official Condition
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Protection	Must be protected from light and excessive moisture.
Container	Keep in the original, tightly closed container.
Child Safety	Store out of the sight and reach of children.

---

For disposal, unused or expired Maxaquin is not recommended for flushing. The preferred method is through an official drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an undesirable substance, sealed in a container, and placed in the household trash. The original container should have all personal information removed before being discarded.